Instil Bio, Inc.
TIL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.01 | 0.05 | -0.09 |
| FCF Yield | -6.13% | -3.70% | -8.48% | -4.60% |
| EV / EBITDA | -6.55 | -6.04 | -23.66 | -25.69 |
| Quality | ||||
| ROIC | -5.94% | -13.00% | -6.38% | -8.89% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.69 | 0.15 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -100.88% | 60.27% | 47.55% | -89.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | -2.33 | -9.12 | -3.91 |
| Interest Coverage | -8.15 | -27.83 | -6.41 | -11.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,922.50 | -51.69 | 29.44 | -119.50 |